107 related articles for article (PubMed ID: 33199152)
1. From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).
Klövekorn P; Pfaffenrot B; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jan; 210():112963. PubMed ID: 33199152
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.
Kircher T; Pantsar T; Oder A; Peter von Kries J; Juchum M; Pfaffenrot B; Kloevekorn P; Albrecht W; Selig R; Laufer S
Eur J Med Chem; 2021 Jan; 209():112901. PubMed ID: 33092905
[TBL] [Abstract][Full Text] [Related]
4. Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors.
Juchum M; Pfaffenrot B; Klövekorn P; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2022 Oct; 240():114584. PubMed ID: 35868124
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Selective Small Molecule Degraders of BRAF-V600E.
Han XR; Chen L; Wei Y; Yu W; Chen Y; Zhang C; Jiao B; Shi T; Sun L; Zhang C; Xu Y; Lee MR; Luo Y; Plewe MB; Wang J
J Med Chem; 2020 Apr; 63(8):4069-4080. PubMed ID: 32223235
[TBL] [Abstract][Full Text] [Related]
6. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
7. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z
ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF
Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK
Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467
[TBL] [Abstract][Full Text] [Related]
9. A Protoberberine derivative HWY336 selectively inhibits MKK4 and MKK7 in mammalian cells: the importance of activation loop on selectivity.
Kim N; Park J; Gadhe CG; Cho SJ; Oh Y; Kim D; Song K
PLoS One; 2014; 9(4):e91037. PubMed ID: 24759688
[TBL] [Abstract][Full Text] [Related]
10. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
11. MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.
Katzengruber L; Sander P; Laufer S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
[TBL] [Abstract][Full Text] [Related]
12. Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.
Zhao K; Lu Y; Chen Y; Cheng J; Zhang W
Exp Cell Res; 2020 May; 390(2):111942. PubMed ID: 32173467
[TBL] [Abstract][Full Text] [Related]
13. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
14. The first small molecules capable of strongly suppressing proliferation of cancer cells harboring BRAF class I/II/III mutations.
Choi SH; Shin I; Kim N; Nam Y; Sim T
Biochem Biophys Res Commun; 2020 Nov; 532(2):315-320. PubMed ID: 32873393
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
[TBL] [Abstract][Full Text] [Related]
16. Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques.
Campos LE; Garibotto FM; Angelina E; Kos J; Tomašič T; Zidar N; Kikelj D; Gonec T; Marvanova P; Mokry P; Jampilek J; Alvarez SE; Enriz RD
Bioorg Chem; 2019 Oct; 91():103125. PubMed ID: 31401373
[TBL] [Abstract][Full Text] [Related]
17. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
18. Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib.
Mathea S; Abdul Azeez KR; Salah E; Tallant C; Wolfreys F; Konietzny R; Fischer R; Lou HJ; Brennan PE; Schnapp G; Pautsch A; Kessler BM; Turk BE; Knapp S
ACS Chem Biol; 2016 Jun; 11(6):1595-602. PubMed ID: 26999302
[TBL] [Abstract][Full Text] [Related]
19. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
20. Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
Brummer C; Faerber S; Bruss C; Blank C; Lacroix R; Haferkamp S; Herr W; Kreutz M; Renner K
Cancer Lett; 2019 Feb; 442():453-463. PubMed ID: 30481565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
